SCHEMBL12082512

SCHEMBL12082512

COC1CCN(Cc2ccc(C)cc2)CC1

nearest known ligand 0.58

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.56
▸ LMNA P02545 1/20 0.56
▸ POLB P06746 1/20 0.56
▸ LTA4H P09960 1/20 0.53
▸ ACHE P22303 1/20 0.52
▸ BACE1 P56817 1/20 0.52
▸ MEN1 O00255 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ HRH1 P35367 1/20 0.51
▸ TEAD1 P28347 1/20 0.51
▸ HRH3 Q9Y5N1 2/20 0.50
▸ OPRM1 P35372 2/20 0.50
▸ OPRK1 P41145 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18082551 0.90 LTA4H (0.55) ALDH1A1LMNAPOLBLTA4HACHE
SCHEMBL791901 0.86 MEN1 (0.55) ALDH1A1LTA4HACHEBACE1MEN1
SCHEMBL28375594 0.85 LTA4H (0.52) ALDH1A1LTA4HACHEMEN1KMT2A
SCHEMBL27891330 0.85 SIGMAR1 (0.63) POLBLTA4HACHEBACE1MEN1
SCHEMBL1428200 0.85 KDM4E (0.53) ALDH1A1LTA4HACHEBACE1HRH3
SCHEMBL3866505 0.85 LTA4H (0.52) LTA4HACHEHRH3OPRM1OPRK1
SCHEMBL3158273 0.85 LMNA (0.57) ALDH1A1LMNALTA4HACHEHRH3
SCHEMBL8096431 0.84 ACHE (0.66) LTA4HACHEBACE1MEN1KMT2A
SCHEMBL12311 0.82 S1PR1 (0.51) ALDH1A1LMNAPOLBLTA4HMEN1
SCHEMBL2237928 0.82 NCF1 (0.63) POLBLTA4HACHEBACE1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2499146-B1 TRICYCLIC PYRAZOL AMINE DERIVATIVES MERCK SERONO SA (CH) 2016-09-21 — — EP disclosed
US-8258129-B2 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-09-04 — — US disclosed
US-20110028715-A1 NOVEL ADENINE COMPOUND DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-02-03 — — US disclosed
US-20110028715-A1 NOVEL ADENINE COMPOUND DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-02-03 — — US disclosed
EP-2206715-A1 Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor Japan Tobacco, Inc. (JP) 2010-07-14 — — EP disclosed
US-20100093998-A1 NOVEL ADENINE COMPOUND DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-04-15 — — US disclosed
US-20100093998-A1 NOVEL ADENINE COMPOUND DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-04-15 — — US disclosed
EP-2133353-A1 NOVEL ADENINE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2009-12-16 — — EP disclosed
US-20090203673-A1 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-08-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028715-A1 NOVEL ADENINE COMPOUND NR0B2, NR0B1, BRD7 ALDH1A1 1664/4885LMNA 3069/4885POLB 1754/4885
US-20100093998-A1 NOVEL ADENINE COMPOUND NR0B2, NR0B1, BRD7 ALDH1A1 1740/4885LMNA 3095/4885POLB 1678/4885
US-20090203673-A1 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS CCNI, MKI67, CCNA1 ALDH1A1 293/4885LMNA 731/4885POLB 1683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback